The first participant has been dosed in the Phase 2 REPAIR-MS clinical trial examining the effects of CNM-Au8, Clene Nanomedicine‘s investigational remyelinating therapy, on brain metabolism in people with multiple sclerosis (MS), the company announced. https://multiplesclerosisnewstoday.com/news-posts/2020/01/09/clene-nanomedicine-announces-first-patient-dosed-in-the-repair-ms-clinical-trial-for-the-treatment-of-multiple-sclerosis-with-lead-nanocatalytic-therapeutic-cnm-au8 Hope 2020 brings in more remyelinating therapies to help with the repair ...